Diabetes News and Research

Latest Diabetes News and Research

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

The VA Maryland Health Care System participated in a landmark national study of more than 10,251 high-risk diabetic adults across the nation, testing if three complementary treatment strategies can reduce the high rate of heart disease and stroke associated with type 2 diabetes and if these treatment strategies can also slow the progression of eye disease associated with diabetes, the leading cause of blindness in working-age Americans.

22 Jul 2010

Survey links autism with digestive problems, intestinal inflammation

Autism is the fastest growing developmental disorder in the world. With 1 child in 91 facing the disorder, the diagnosis is more common than pediatric cancer, diabetes, and AIDS combined.

22 Jul 2010

DenteMax offers largest network approved for Medicare dental benefits

DenteMax, the nation's largest seamless dental PPO network, now also offers the largest seamless network approved for Medicare dental benefits. The new network provides access to more than 65,000 approved dentist access points and is built on the strong foundation of the commercial DenteMax network.

22 Jul 2010

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Ampio Pharmaceuticals, Inc. today announced the initiation of a Phase II clinical trial of Optina™ for the treatment of diabetic macular edema, an early stage of diabetic retinopathy. Diabetic macular edema is responsible for most vision loss in patients with diabetes mellitus.

22 Jul 2010

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

Tethys Bioscience, Inc., a privately held company, announced today that the company has recently raised $33 million, comprising $23 million of venture financing and a $10 million working capital loan. Participants in the venture financing included new investors Greenspring Associates, Inc. (formerly Montagu Newhall Associates, Inc.) and Paul Capital Investments, as well as current investors.

21 Jul 2010

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

AMRI has commenced enrollment for a Phase I study of ALB-127158(a), a novel MCH1 receptor antagonist offering a potential new approach for the treatment of obesity. The announcement was made yesterday during a presentation by AMRI's Dr. Peter Guzzo, director, discovery research and development, at the 6th Obesity and Diabetes Drug Development Summit in Arlington, VA. Preclinical data were also reported.

21 Jul 2010

Health Canada grants Osiris Priority Review for Prochymal NDS

Osiris Therapeutics, Inc. announced today that the Biologics and Genetic Therapies Directorate of Health Canada has completed its initial evaluation and accepted for full review the company's New Drug Submission (NDS) of Prochymal (remestemcel-L), an adult stem cell therapy for the treatment of graft vs. host disease (GvHD). Based on a separate review of summary clinical data, Health Canada has notified Osiris that the application has been granted Priority Review, shortening the examination period from 300 to 180 days.

21 Jul 2010

Researchers find that increase in leptin may promote colorectal neoplasms

Now, for the first time, a collaborative study of researchers at the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University's College of Science and Technology and the Department of Hematology, Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy have found that an increase in leptin, a cytokine that is normally increased in obese or overweight individuals, may promote colorectal neoplasms by activating colorectal cancer stem cells.

21 Jul 2010

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Abbott today announced financial results for the second quarter ended June 30, 2010.

21 Jul 2010

Study: Americans with stand-alone vision insurance plans more likely to receive annual eye examination

According to a new study conducted for the National Association of Vision Care Plans by an independent research firm, health care consumers who participate in full service, stand-alone vision insurance plans are two times (33.3 percent) more likely to receive an annual comprehensive eye examination than those consumers that have vision care coverage "bundled" with their major medical plan (16.3 percent).

21 Jul 2010

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

New research from The Methodist Hospital in Houston shows that sepsis is 10 times more common and more lethal than other more well-known surgical complications including heart attacks and blood clots. These results, published today in the Archives of General Surgery, show a greater need for sepsis awareness and early recognition during and after surgery.

21 Jul 2010

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

Results from the landmark AIDS Treatment for Life International Survey, a multi-country survey of more than 2,000 people living with HIV/AIDS, revealed a significant gap in patient-physician dialogue about critical health-related conditions that may negatively impact patients' overall long-term health, quality of life, and treatment outcomes.

21 Jul 2010

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

A combination of nutrients called NT-020 promoted adult neural stem cell proliferation in aged rats and boosted their memory performance, reported University of South Florida researchers studying natural therapeutic approaches to promoting the health of neurons in the aging brain.

21 Jul 2010

UDCA fails to improve overall histology in NASH patients: Study

A study conducted by researchers at Johann Wolfgang Goethe University in Frankfurt, Germany found that high doses of ursodeoxycholic acid, suggested by some studies to have a beneficial effect on nonalcoholic steatohepatitis, does not improve overall histology in these patients. Full findings of this study are published in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

21 Jul 2010

California companies are developing new medicines for diabetes: Report

Pharmaceutical research and biotechnology companies based in California are researching and developing 58 new medicines for diabetes, a chronic disease that afflicts 220 million patients worldwide, including 23.6 million Americans, a new report shows.

21 Jul 2010

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Researchers from the La Jolla Institute for Allergy & Immunology have joined forces with the Dana-Farber Cancer Institute in Boston and Washington University in St. Louis to investigate a potential new therapy for sickle cell disease, a severe and chronic illness affecting more than 70,000 Americans and several million people worldwide.

21 Jul 2010

Study demonstrates direct link between juvenile compensatory growth and reproduction

University of California, Riverside biologists working on guppies - small freshwater fish that have been the subject of long-term studies - report that rapid growth responses to increased food availability after a period of growth restriction early in life have repercussions in adulthood.

21 Jul 2010

Lannett's ANDA for Phentermine Hydrochloride Blue/White Seed Capsules receives FDA approval

Lannett Company, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Phentermine Hydrochloride Blue/White Seed Capsules USP, 30 mg, the generic equivalent of Sandoz, Inc.'s Reference Listed Drug (RLD) Phentermine Hydrochloride Capsules USP, 30 mg.

21 Jul 2010

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.

21 Jul 2010

Forest Laboratories reports first-quarter diluted EPS of $0.39

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $0.39 in the first quarter of fiscal 2011. Excluding the charge related to the United States Department of Justice investigations described below, and a charge of $50.0 million, or $0.17 per share net of tax, for a new product licensing fee, non-GAAP earnings per share for the first fiscal quarter were $0.95 per share.

20 Jul 2010

Diabetes News and Research

Latest Diabetes News and Research

Study identifies treatment strategies that can slow progression of eye disease associated with diabetes

Survey links autism with digestive problems, intestinal inflammation

DenteMax offers largest network approved for Medicare dental benefits

Ampio Pharmaceuticals commences Optina Phase II clinical trial for diabetic macular edema

Tethys Bioscience raises $33 million to drive market uptake of PreDx Diabetes Risk Score blood test

AMRI initiates enrollment for Phase I study of ALB-127158 for obesity

Health Canada grants Osiris Priority Review for Prochymal NDS

Researchers find that increase in leptin may promote colorectal neoplasms

Abbott second-quarter global sales increase 17.8% to $8.8 billion

Study: Americans with stand-alone vision insurance plans more likely to receive annual eye examination

Study finds sepsis 10 times more common and lethal than heart attacks, blood clots

ATLIS 2010 shows gap in patient-physician dialogue that may negatively impact patients' quality of life

NT-020 nutrients promote adult neural stem cell growth in aged rats: Researchers

UDCA fails to improve overall histology in NASH patients: Study

California companies are developing new medicines for diabetes: Report

La Jolla Institute forms partnership to investigate potential new therapy for sickle cell disease

Study demonstrates direct link between juvenile compensatory growth and reproduction

Lannett's ANDA for Phentermine Hydrochloride Blue/White Seed Capsules receives FDA approval

FDA accepts MannKind's resubmission of AFREZZA NDA, sets PDUFA action date

Forest Laboratories reports first-quarter diluted EPS of $0.39

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Diabetes News and Research

Latest Diabetes News and Research

Evolving spectrophotometry for modern biopharma workflows

Scaling B-cell cloning workflows for antibody development

Fluidics in Modern Healthcare & Medical Device Innovation

Newsletters you may be interested in